OBJECTIVE: The purpose of this study was to evaluate the effect of neoadjuvant chemotherapy (NAC) on the responses and survival rates of patients with different molecular subtypes of breast cancer. METHODS: A retrospective analysis was conducted on 284 breast cancer patients who underwent NAC in our hospital from January 2017 to January 2019. The patients were classified into the Luminal A (n=87), Luminal B (n=78), human epidermal growth factor receptor 2 positive (HER-2+, n=66), and triple-negative (TN, n=53) breast cancer subtypes. The Ki67 expressions and clinical prognoses were compared among the patients in the four subtypes. RESULTS: The complete response (CR) rates were significantly higher in the HER-2+ and TN patients than they were in the Luminal A and Luminal B subtype patients (P<0.05). The HER-2+ and TN breast cancer patients had significantly higher response rates (RR) than the Luminal B patients (P<0.05). The Ki67 expressions decreased significantly in the patients with the Luminal B, HER-2+, and TN subtypes after NAC (P<0.05), with a greater decrease in the Ki67 expressions in the HER-2+ and TN subtypes than in the Luminal B subtypes (P<0.05). The Ki67 levels decreased significantly in the patients with CR or PR compared to the stable disease (SD) and progressive disease (PD) patients (P<0.05). The HER-2+ patients had remarkably higher distant metastasis rates, compared to the patients with the Luminal A and B subtypes (P<0.05). CONCLUSION: Statistical differences were found in the pathological responses and survival rates in the patients with the different molecular subtypes of breast cancer after the NAC treatment. The HER-2+ or TN breast cancer patients had higher pathological response rates, which may be closely related to their decreased Ki67 expressions. Interestingly, the HER-2+ breast cancer patients also showed a higher distant metastasis rate, which warrants further analysis. AJTR
OBJECTIVE: The purpose of this study was to evaluate the effect of neoadjuvant chemotherapy (NAC) on the responses and survival rates of patients with different molecular subtypes of breast cancer. METHODS: A retrospective analysis was conducted on 284 breast cancer patients who underwent NAC in our hospital from January 2017 to January 2019. The patients were classified into the Luminal A (n=87), Luminal B (n=78), human epidermal growth factor receptor 2 positive (HER-2+, n=66), and triple-negative (TN, n=53) breast cancer subtypes. The Ki67 expressions and clinical prognoses were compared among the patients in the four subtypes. RESULTS: The complete response (CR) rates were significantly higher in the HER-2+ and TN patients than they were in the Luminal A and Luminal B subtype patients (P<0.05). The HER-2+ and TN breast cancer patients had significantly higher response rates (RR) than the Luminal B patients (P<0.05). The Ki67 expressions decreased significantly in the patients with the Luminal B, HER-2+, and TN subtypes after NAC (P<0.05), with a greater decrease in the Ki67 expressions in the HER-2+ and TN subtypes than in the Luminal B subtypes (P<0.05). The Ki67 levels decreased significantly in the patients with CR or PR compared to the stable disease (SD) and progressive disease (PD) patients (P<0.05). The HER-2+ patients had remarkably higher distant metastasis rates, compared to the patients with the Luminal A and B subtypes (P<0.05). CONCLUSION: Statistical differences were found in the pathological responses and survival rates in the patients with the different molecular subtypes of breast cancer after the NAC treatment. The HER-2+ or TN breast cancer patients had higher pathological response rates, which may be closely related to their decreased Ki67 expressions. Interestingly, the HER-2+ breast cancer patients also showed a higher distant metastasis rate, which warrants further analysis. AJTR
Authors: Pat Whitworth; Peter Beitsch; Angela Mislowsky; James V Pellicane; Charles Nash; Mary Murray; Laura A Lee; Carrie L Dul; Michael Rotkis; Paul Baron; Lisette Stork-Sloots; Femke A de Snoo; Jennifer Beatty Journal: Ann Surg Oncol Date: 2016-10-21 Impact factor: 5.344
Authors: Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen Journal: J Natl Cancer Inst Date: 2009-05-12 Impact factor: 13.506